Skip to main content

NICE TAs

02/04/2025
TA1051: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over
27/03/2025
TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
27/03/2025
TA1048: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable
27/03/2025
TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
12/03/2025
TA1046: Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
05/03/2025
TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
26/02/2025
TA1043: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
26/02/2025
TA1044: Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over
19/02/2025
TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
19/02/2025
TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer
02/10/2024
TA1009: Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
17/09/2024
TA1007: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
29/08/2024
TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
07/08/2024
TA993: Burosumab for treating X-linked hypophosphataemia in adults
07/08/2024
TA991: Abaloparatide for treating osteoporosis after menopause
13/06/2024
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
05/06/2024
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
08/05/2024
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
08/05/2024
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
28/03/2024
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Follow AWTTC: